The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients...
The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved talazoparib (Talzenna) in combination with the antiandrogen therapy enzalutamide...
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to glofitamab-gxbm (Columvi) for select patients with B-cell...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate cancer The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza), in combination with...
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for certain...
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq (Polivy), in combination with a rituximab product,...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and infection The U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for adult and pediatric...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration (FDA) has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to retifanlimab-dlwr (Zynyz) for the treatment of adult...
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration (FDA) has approved dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for pediatric patients 1 year...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 54,000 members worldwide drive progress against cancer.
Donate Now